Physician profile
Eric D Achtyes
NPI 1780665976
$86,759.34
in general payments reported to CMS, 2019-2025
16 companies · $14K in 2025
The $14K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,425 · 2020: $16K · 2021: $15K · 2022: $6,373 · 2023: $12K · 2024: $15K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $25K · Travel and Lodging: $8,332 · Honoraria: $4,038 · Food and Beverage: $2,549 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $199 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $25,467.50 |
| Travel and Lodging | $8,332.05 |
| Honoraria | $4,038.00 |
| Food and Beverage | $2,548.85 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $199.00 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| H. Lundbeck A S | $35,829.93 | 2019-2023 | Abilify Maintena |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25,764.39 | 2023-2025 | |
| Alkermes, INC. | $11,120.58 | 2019-2024 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $5,163.04 | 2020-2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $3,579.97 | 2020-2025 | Austedo Xr |
| Sunovion Pharmaceuticals INC. | $2,133.36 | 2020-2022 | |
| Indivior INC. | $1,787.50 | 2023 | Perseris |
| F. Hoffmann-La Roche Ag | $1,202.50 | 2019 | |
| Janssen Scientific Affairs, LLC | $150.80 | 2020-2025 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $27.27 | 2024 | Cobenfy |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Achtyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.